Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Pigment Cell and Melanoma Research

Volumn 27, Issue 4, 2014, Pages 590-600

  Young, Richard J ^a   Waldeck, Kelly ^a   Martin, Claire ^a   Foo, Jung H ^a   Cameron, Donald P ^a   Kirby, Laura ^a   Do, Hongdo ^a,b   Mitchell, Catherine ^a   Cullinane, Carleen ^a,c   Liu, Wendy ^a   Fox, Stephen B ^a,c   Dutton Regester, Ken ^d   Hayward, Nicholas K ^d   Jene, Nicholas ^a   Dobrovic, Alexander ^a,b,c   Pearson, Richard B ^a,c   Christensen, James G ^e   Randolph, Sophia ^e   Mcarthur, Grant A ^a,c   Sheppard, Karen E ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e PFIZER INC   (United States)

Author keywords

CDK4; CDKN2A; Cyclin D1; Melanoma; PD0332991; RB1

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PALBOCICLIB; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 6; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MELANOMA CELL LINE; ONCOGENE N RAS; PROTEIN EXPRESSION; WILD TYPE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84902546671     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12228     Document Type: Article

References (40)

1. Barretina, J., Caponigro, G., Stransky, N. et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607.
2. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
3. Comstock, C.E., Augello, M.A., Goodwin, J.F. et al. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene 32, 5481-5491.
4. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
5. Dean, J.L., McClendon, A.K., Hickey, T.E., Butler, L.M., Tilley, W.D., Witkiewicz, A.K., and Knudsen, E.S. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11, 2756-2761.
6. Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C.Y., Dobrovic, A., and McArthur, G. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24, 666-672.
7. Dutton-Regester, K., Irwin, D., Hunt, P. et al. (2012). A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11, 888-897.
8. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917.
9. Finn, R.S., Dering, J., Conklin, D. et al. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77.
10. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
11. Forbes, S.A., Bindal, N., Bamford, S. et al. (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950.
12. Fry, D.W., Harvey, P.J., Keller, P.R. et al. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438.
13. Hacker, E., Muller, H.K., Irwin, N. et al. (2006). Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res. 66, 2946-2952.
14. Hacker, E., Hayward, N.K., Dumenil, T., James, M.R., and Whiteman, D.C. (2010). The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130, 241-248.
15. Handolias, D., Salemi, R., Murray, W., Tan, A., Liu, W., Viros, A., Dobrovic, A., Kelly, J., and McArthur, G.A. (2010). Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res. 23, 210-215.
16. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A., and Dean, D.C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859-869.
17. Houben, R., Becker, J.C., Kappel, A., Terheyden, P., Brocker, E.B., Goetz, R., and Rapp, U.R. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3, 6.
18. Hussussian, C.J., Struewing, J.P., and Goldstein, A.M. (1994). Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15-21.
19. Kamb, A., Shattuck-Eidens, D., Eeles, R. et al. (1994). Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 23-26.
20. Knudsen, E.S., and Knudsen, K.E. (2008). Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 8, 714-724.
21. Konecny, G.E., Winterhoff, B., Kolarova, T. et al. (2011). Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin. Cancer Res. 17, 1591-1602.
22. Krimpenfort, P., Quon, K.C., Mooi, W.J., Loonstra, A., and Berns, A. (2001). Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83-86.
23. Leonard, J.P., Lacasce, A.S., Smith, M.R. et al. (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119, 4597-4607.
24. Li, Y., Nichols, M.A., Shay, J.W., and Xiong, Y. (1994). Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54, 6078-6082.
25. Lim, A.M., Do, H., Young, R.J. et al. (2014). Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int. J. Cancer. doi: 10.1002/ijc.28727 [Epub ahead of print].
26. Liu, W., Kelly, J.W., Trivett, M. et al. (2007). Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127, 900-905.
27. Logan, J.E., Mostofizadeh, N., Desai, A.J. et al. (2013). PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 33, 2997-3004.
28. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
29. Lundberg, A.S., and Weinberg, R.A. (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18, 753-761.
30. Michaud, K., Solomon, D.A., Oermann, E., Kim, J.S., Zhong, W.Z., Prados, M.D., Ozawa, T., James, C.D., and Waldman, T. (2010). Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228-3238.
31. Monks, A., Scudiero, D., Skehan, P. et al. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83, 757-766.
32. Rane, S.G., Cosenza, S.C., Mettus, R.V., and Reddy, E.P. (2002). Germ line transmission of the Cdk 4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell. Biol. 22, 644-656.
33. Sanki, A., Li, W., and Colman, M. (2007). Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology 39, 551-557.
34. Sharpless, N.E., Bardeesy, N., Lee, K.H., Carrasco, D., Castrillon, D.H., Aguirre, A.J., Wu, E.A., Horner, J.W., and Depinho, R.A. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91.
35. Sheppard, K.E., and McArthur, G.A. (2013). The Cell Cycle regulator CDK4 an emerging therapeutic target in melanoma. Clin. Cancer Res. 19, 5320-5328.
36. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., and Boyd, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst. 82, 1107-1112.
37. Sotillo, R., Dubus, P., Martin, J., De La Cueva, E., Ortega, S., Malumbres, M., and Barbacid, M. (2001). Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20, 6637-6647.
38. Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642.
39. Walker, G.J., Flores, J.F., Glendening, J.M., Lin, A.H., Markl, I.D., and Fountain, J.W. (1998). Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosom. Cancer 22, 157-163.
40. Zuo, L., Weger, J., Yang, Q., Goldstein, A.M., Tucker, M.A., Walker, G.J., Hayward, N., and Dracopoli, N.C. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97-99.